# US 11,306,057 B2 · Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,306,057 B2
- Document ID: US11306057B2
- Status: Granted
- Kind: B2
- Application number: 16/878,507
- Filed: 2020-05-19
- Published: 2021-01-28
- Granted: 2022-04-19
- Earliest claimed: 2011-01-03
- Assignees: The William M. Yarbrough Foundation
- Applicants: Michael E. Silver
- Inventors: Michael E. Silver
- Web page: https://patentgrep.com/patent/US11306057B2

## CPC

- C07C 331/20: of a saturated carbon skeleton
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 31/145: having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2) (isothiourea A61K31/155)
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/26: Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods, formulations, and compositions for the treatment of biofilms. In particular, the application discloses isothiocyanate functional surfactants either alone or combination with adjunct agents to treat biofilms. One suitable isothiocyanate functional surfactant is represented by the following chemical structure:

## Claims

### Claim 1

A method, comprising the step of administering to a patient having a biofilm an isothiocyanate functional surfactant, wherein the surfactant comprises a lysine derivative having an α-nitrogen and a ϵ-nitrogen, and wherein an alkyl substituent comprising at least 8 carbon atoms is bound to the α-nitrogen, and further wherein the ϵ-nitrogen forms part of an isothiocyanate functional group.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the composition comprising the isothiocyanate functional surfactant is administered to the patient at least one of orally, intravenously, intramuscularly, intrathecally, cutaneously, subcutaneously, transdermally, sublingually, buccally, rectally, vaginally, ocularly, otically, and nasally.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the composition comprising the isothiocyanate functional surfactant is topically administered to the patient.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the amount of isothiocyanate functional surfactant in the composition topically administered to the patient ranges from approximately 0.5 nmol/cm2 to approximately 10 μmol/cm2.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the composition comprising the isothiocyanate functional surfactant is a topical preparation selected from the group consisting of ointment, cream, emulsion, lotion and gel.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the composition further comprises one or more pharmaceutical, biological or molecular biological active agents.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the patient is a mammal.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the mammal is a human.